The effects of group cycling on gait and pain-related disability in individuals with mild-to-moderate knee osteoarthritis: a randomized controlled trial.

Study Design: Randomized controlled trial.
Objective: To determine the effectiveness of a community-based program of stationary group cycling on gait, pain, and physical function in individuals with mild-to-moderate knee osteoarthritis (OA).
Background: Knee pain and disability are common symptoms in individuals with knee OA. Though exercise for knee OA has acknowledged benefits, it has the potential to aggravate symptoms in some instances.
Methods: Thirty-seven subjects (27 women, 10 men) with a mean ± SD age of 57.7 ± 9.8 years were randomly assigned to a cycling (n = 19) or control (n = 18) group for a 12-week intervention study. Outcome variables, measured at baseline and 12 weeks, included preferred and maximal gait velocity, a visual analog pain scale at rest and following a 6-minute walk test, muscle strength, and functional-outcome questionnaires. Data were analyzed using mixed-model analyses of variance for group and time differences.
Results: After 12 weeks, the individuals receiving the cycling intervention showed significantly greater improvements (P<.05) for preferred gait velocity (mean difference between groups, 8.7 cm/s; 95% confidence interval [CI]: 2.2, 15.1), visual analog pain scale on the 6-minute walk test (mean difference, 16.5 mm; 95% CI: 2.1, 31.0), the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale (mean difference, 14.9 points; 95% CI: 2.6, 27.0) and stiffness subscale (mean difference, 10.8 points; 95% CI: 0.7, 21.3), the Knee injury and Osteoarthritis Outcome Score pain subscale (mean difference, 13.3 points; 95% CI: 3.4, 23.3), and the Knee Outcome Survey activities of daily living subscale (mean difference, 13.9 points; 95% CI: 2.0, 25.9) compared to controls.
Conclusion: Stationary group cycling may be an effective exercise option for individuals with mild-to-moderate knee OA and may reduce pain with walking. US trial registration NCT00917618.
Level of Evidence: Therapy, level 1b-.